drugset

drugset / Trial / NCT00447629

Study Evaluating Single Doses of PPM-204 on the Electrical Pathways of the Heart

NCT00447629 ↗

Phase 1 Completed Wyeth is now a wholly owned subsidiary of Pfizer

RandomizedCrossoverDouble-blindDiagnostic

Summary

A study evaluating the safety of a high and low dose of PPM-204 on the electrical pathways of the heart.

Timeline

Start: 2007-01
Primary completion: —
Completion: 2007-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	INDEGLITAZAR	Small molecule	—	Oral

Indications